13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001263508
Total reported value
$20.0B
$20.0B
91 檔
42.4%
In Q3 2025, Baker Bros. Advisors LP's U.S. equity holdings reached a combined market value of $20.0B, distributed across 91 disclosed stock positions.
In Q3 2025, Baker Bros. Advisors LP displayed an active expansion posture, initiating 22 new positions and adding to 25 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ONC | Beone Medicines Ltd-adr | Stock-Other | 21.66% | -2.43% | — | |
| 2 | INCY | Incyte CORP | Stock-Healthcare | 18.84% | +0.86% | +0.00% | |
| 3 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 7.10% | -0.67% | +8.38% | |
| 4 | INSM | Insmed Inc | Stock-Healthcare | 6.98% | -2.27% | -13.09% | |
| 5 | ACAD | Acadia Pharmaceuticals Inc | Stock-Healthcare | 6.61% | -0.04% | — | |
| 6 | SMMT | Summit Therapeutics Inc | Stock-Other | 5.03% | -1.57% | — | |
| 7 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 4.09% | +0.32% | — | |
| 8 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 3.19% | +5.40% | +0.97% | |
| 9 | CELC | Celcuity Inc | Stock-Other | 2.83% | -1.04% | +45.23% | |
| 10 | KYMR | Kymera Therapeutics Inc | Stock-Other | 2.72% | +0.83% | — | |
| 11 | KOD | Kodiak Sciences Inc | Stock-Other | 2.05% | -0.47% | — | |
| 12 | ALKS | Alkermes plc | Stock-Healthcare | 1.75% | +0.60% | +26.22% | |
| 13 | ABCL | Abcellera Biologics Inc | Stock-Other | 1.00% | +0.69% | — | |
| 14 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 0.86% | -0.44% | — | |
| 15 | KNSA | Kiniksa Pharmaceuticals International, plc | Stock-Other | 0.79% | +0.13% | — | |
| 16 | STOK | Stoke Therapeutics Inc | Stock-Other | 0.79% | -0.07% | — | |
| 17 | ✓ | Immatics NV | Stock-Other | 0.74% | -0.14% | +18.93% | |
| 18 | GRAL | Grail Inc | Stock-Healthcare | 0.70% | +0.18% | — | |
| 19 | IDYA | Ideaya Biosciences Inc | Stock-Other | 0.64% | +0.18% | +54.59% | |
| 20 | IMVT | Immunovant Inc | Stock-Other | 0.64% | +0.27% | — | |
| 21 | IMCR | Immunocore Holdings Plc-adr | Stock-Other | 0.61% | -0.13% | EXIT | |
| 22 | BCYC | Bicycle Therapeutics Plc-adr | Stock-Other | 0.61% | -0.06% | — | |
| 23 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 0.60% | — | — | |
| 24 | ABVX | Abivax Sa-adr | Stock-Other | 0.54% | -0.56% | EXIT | |
| 25 | ARWR | Arrowhead Pharmaceuticals In | Stock-Healthcare | 0.42% | +0.09% | +77.90% | |
| 26 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 0.41% | +0.07% | — | |
| 27 | DNLI | Denali Therapeutics Inc | Stock-Other | 0.39% | +0.07% | — | |
| 28 | ✓ | Merus N V | Stock-Other | 0.39% | — | — | |
| 29 | NTLA | Intellia Therapeutics Inc | Stock-Other | 0.34% | +0.08% | NEW | |
| 30 | REPL | Replimune Group Inc | Stock-Other | 0.33% | +0.12% | — | |
| 31 | RAPP | Rapport Therapeutics Inc | Stock-Other | 0.33% | +0.04% | +181.24% | |
| 32 | GPCR | Structure Therapeutics Inc | Stock-Other | 0.31% | -0.01% | -37.97% | |
| 33 | CELC 2.75 08-01-31Bond | Celcuity Inc | Bond | 0.30% | -0.08% | — | |
| 34 | VRDN | Viridian Therapeutics Inc | Stock-Other | 0.27% | — | — | |
| 35 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 0.27% | -0.07% | — | |
| 36 | PRAX | Praxis Precision Medicines I | Stock-Other | 0.26% | -0.30% | — | |
| 37 | GLUE | Monte Rosa Therapeutics Inc | Stock-Other | 0.26% | +0.12% | — | |
| 38 | BNTX | Biontech Se-adr | Stock-Other | 0.26% | — | — | |
| 39 | NRIX | Nurix Therapeutics Inc | Stock-Other | 0.26% | +0.16% | — | |
| 40 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 0.22% | +0.01% | — | |
| 41 | TRDA | Entrada Therapeutics Inc | Stock-Other | 0.20% | -0.18% | — | |
| 42 | ARGX | Argenx Se - Adr | Stock-Healthcare | 0.20% | -0.11% | EXIT | |
| 43 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 0.20% | — | — | |
| 44 | PCVX | Vaxcyte Inc | Stock-Other | 0.17% | — | — | |
| 45 | IRON | Disc Medicine Inc | Stock-Other | 0.16% | — | — | |
| 46 | CDTX | Cidara Therapeutics Inc | Stock-Other | 0.16% | — | — | |
| 47 | CLDX | Celldex Therapeutics Inc | Stock-Other | 0.12% | +0.10% | — | |
| 48 | NGNE | Neurogene Inc | Stock-Other | 0.12% | +0.05% | — | |
| 49 | SERA | Sera Prognostics Inc-a | Stock-Other | 0.12% | -0.01% | — | |
| 50 | SYRE | Spyre Therapeutics Inc | Stock-Other | 0.12% | -0.29% | EXIT |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | INSM | Insmed Inc | +2.4% | -13.09% | Add |
| 2 | CELC | Celcuity Inc | +2.4% | +45.23% | Add |
| 3 | KOD | Kodiak Sciences Inc | +1.5% | — | Unchanged |
| 4 | KYMR | Kymera Therapeutics Inc | +0.9% | — | Add |
| 5 | RYTM | Rhythm Pharmaceuticals Inc | +0.8% | — | Unchanged |
| 6 | STOK | Stoke Therapeutics Inc | +0.5% | — | Unchanged |
| 7 | IDYA | Ideaya Biosciences Inc | +0.5% | +54.59% | Add |
| 8 | ✓ | Immatics NV | +0.4% | +18.93% | Add |
| 9 | ABCL | Abcellera Biologics Inc | +0.3% | — | Unchanged |
| 10 | ✓ | Merus N V | +0.3% | — | Add |
| 11 | NTLA | Intellia Therapeutics Inc | +0.3% | +2.65% | Add |
| 12 | GRAL | Grail Inc | +0.2% | — | Unchanged |
| 13 | GPCR | Structure Therapeutics Inc | +0.2% | -37.97% | Add |
| 14 | BNTX | Biontech Se-adr | +0.2% | — | Add |
| 15 | IONS | Ionis Pharmaceuticals Inc | +0.2% | — | Add |
| 16 | PRAX | Praxis Precision Medicines I | +0.1% | — | Add |
| 17 | IRON | Disc Medicine Inc | +0.1% | — | Add |
| 18 | ALKS | Alkermes plc | +0.1% | +26.22% | Add |
| 19 | KNSA | Kiniksa Pharmaceuticals International, plc | +0.1% | — | Add |
| 20 | RVMD | Revolution Medicines Inc | +0.1% | +0.97% | Add |
| 21 | CLDX | Celldex Therapeutics Inc | +0.1% | — | Add |
| 22 | SION | Sionna Therapeutics Inc | 0% | — | Unchanged |
| 23 | TSHA | Taysha Gene Therapies Inc | 0% | — | Unchanged |
| 24 | PRLD | Prelude Therapeutics Inc | 0% | — | Unchanged |
| 25 | DSGN | Design Therapeutics Inc | 0% | — | Trim |
| 26 | SGMT | Sagimet Biosciences Inc-a | 0% | — | Unchanged |
| 27 | GLUE | Monte Rosa Therapeutics Inc | 0% | — | Unchanged |
| 28 | XNCR | Xencor Inc | 0% | +64.39% | Add |
| 29 | SANA | Sana Biotechnology Inc | 0% | — | Unchanged |
| 30 | SKYE | Skye Bioscience Inc | 0% | — | Unchanged |
| 31 | RLAY | Relay Therapeutics Inc | 0% | — | Unchanged |
| 32 | DBVT | Dbv Technologies Sa-spon Adr | — | — | Unchanged |
| 33 | VTVT | Vtv Therapeutics Inc- Cl A | — | +52.41% | Add |
| 34 | TCRX | Tscan Therapeutics Inc | — | — | Unchanged |
| 35 | ALGS | Aligos Therapeutics Inc | — | — | Unchanged |
| 36 | ELVN | Enliven Therapeutics Inc | — | — | Unchanged |
| 37 | TYRA | Tyra Biosciences Inc | — | — | Unchanged |
| 38 | SRZNW | Surrozen Inc-cw25 | — | — | Unchanged |
| 39 | ACRV | Acrivon Therapeutics Inc | — | — | Unchanged |
| 40 | OPTEY | Opthea Ltd-spon Adr | — | — | Unchanged |
| 41 | ROIV | Roivant Sciences Ltd. | 0% | — | Unchanged |
| 42 | CTNM | Contineum Therapeutics Inc-a | 0% | -75.15% | Trim |
| 43 | WVE | Wave Life Sciences Ltd. | 0% | — | Unchanged |
| 44 | TECX | Tectonic Therapeutic Inc | 0% | — | Unchanged |
| 45 | TARA | Protara Therapeutic Inc | 0% | — | Unchanged |
| 46 | XENE | Xenon Pharmaceuticals Inc | 0% | — | Add |
| 47 | VIR | Vir Biotechnology Inc | 0% | — | Unchanged |
| 48 | RARE | Ultragenyx Pharmaceutical In | 0% | — | Add |
| 49 | ALMS | Alumis Inc | -0.1% | — | Unchanged |
| 50 | KALAEUR | Kala Bio Inc | -0.1% | -18.04% | Trim |
According to official SEC Form 13F filings, Baker Bros. Advisors LP reported a total U.S. public equity portfolio value of $20.0B across 91 disclosed positions in Q3 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ONC, INCY, MDGL) accounted for 42.4% of total reported equity market value during Q3 2025.
Top New Position Initiated
ABVX
市值: $74.4M
Top Position Liquidated / Trimmed
INSM 0.75 06-01-28
前期市值: $101.6M
During Q3 2025, Baker Bros. Advisors LP's top holdings by market value included ONC (21.7%)、INCY (18.8%)、MDGL (7.1%). The largest single position, ONC, represented 21.7% of total portfolio value.
In Q3 2025, Baker Bros. Advisors LP made 74 total portfolio adjustments, initiating 22 new buys, adding to 25 positions, trimming 7 holdings, and fully liquidating 20 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.